Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Renovorx Inc
(NQ:
RNXT
)
1.010
+0.040 (+4.09%)
Streaming Delayed Price
Updated: 3:42 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Renovorx Inc
< Previous
1
2
3
Next >
RenovoRx CEO Issues Update Letter to Shareholders
May 30, 2024
From
RenovoRx, Inc.
Via
Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
May 21, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
May 14, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
May 02, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
April 18, 2024
From
RenovoRx , Inc.
Via
Business Wire
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
April 16, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
April 15, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces $11.1 Million at Market Private Placement
April 08, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
April 05, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
March 12, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Highlights Key Leadership Promotions
March 08, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx CEO Issues Letter to Shareholders
February 06, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Closes $6.1 Million Private Placement
January 29, 2024
From
RenovoRx, Inc.
Via
Business Wire
Clinical Trials at Major University; New Application Targeting Tumors with an IP Portfolio of 9 Patents Issued, 9 Pending for Cancer Treatments Partnered with Imugene: RenovoRx (NASDAQ: RNXT)
December 28, 2023
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials
December 21, 2023
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
December 21, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
December 19, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
December 13, 2023
From
RenovoRx, Inc.
Via
Business Wire
Biopharma Company Reaches Phase 3 Clinical Trials for Cancer Treatments; 9 Patents Issued; Collaboration with Imugene: RenovoRx (NASDAQ: RNXT)
December 12, 2023
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
November 16, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
November 14, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
October 02, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
August 17, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
July 31, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
July 20, 2023
Via
Get News
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
July 20, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
July 20, 2023
Via
TheNewswire.com
RenovoRx, Inc. Stock Presents A Compelling Value Proposition After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
July 11, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
RenovoRx, Inc. Stock Surges After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
July 05, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
June 29, 2023
RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an...
Via
TheNewswire.com
Exposures
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.